A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

@article{DAndrea2005API,
  title={A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.},
  author={Giovanna D’Andrea and Rosa Lucia D'Ambrosio and Pasquale Di Perna and Massimiliano Chetta and Rosa Santacroce and Vincenzo F. Brancaccio and Elvira Grandone and Maurizio Margaglione},
  journal={Blood},
  year={2005},
  volume={105 2},
  pages={
          645-9
        }
}
Patients require different warfarin dosages to achieve the target therapeutic anticoagulation. The variability is largely genetically determined, and it can be only partly explained by genetic variability in the cytochrome CYP2C9 locus. In 147 patients followed from the start of anticoagulation with warfarin, we have investigated whether VKORC1 gene mutations have affected doses of drug prescribed to acquire the target anticoagulation intensity. Two synonymous mutations, 129C>T at Cys43 and… 
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
INTRODUCTION Warfarin is currently considered to be the anticoagulant of choice in the long-term treatment and prevention of thromboembolic events. However, it presents a narrow therapeutic range and
Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice.
TLDR
It was proven that genetic variability in two genes, CYP2C9 a VKORC1, has a significant influence on the individual's response to the dosage of warfarin.
Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
TLDR
In obese patients and in obese patients, warfarin maintenance doses were significantly higher than in the others, and in VKORC1 1173CT, 1542GC, 2255CT and 3730CT polymorphisms were detected in same patients, but CYP2C9 exon 4 −65GC carriers were different from them.
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
TLDR
Analysis of the combination of VKORC1 and CYP2C9 genotypes should identify warfarin-sensitive patients who require a lower dose of drug, allowing personalized warfarIn treatment.
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation
TLDR
The consistent findings regarding the role of VKORC1 and CYP2C9 in warfarin metabolism and maintenance dosage represent a clinically useful proof of principal for the use of pharmacogenomic information in medicine and may lead to improved understanding of warFarin’s actions.
1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose
TLDR
It is suspected that the actual change that defines the relative resistance to warfarin may be present in the proximity of these two polymorphisms, based on the complete linkage disequilibrium between 1173C > T and 3730G > A polymorphisms.
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
TLDR
The differences in allele frequencies of A/G allele and its levels of VKORC1 promoter activity may underscore the inter-individual differences in warfarin dosage as well as inter-ethnic differences between Chinese and Caucasians.
The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
TLDR
This study showed that in the heart valve replacement patients considering VKORC1 and CYP2C9 polymorphisms beside demographic characteristics such as age will be helpful in pre-treatment dosing of warfarin which in turn reduces the complications associated with inappropriate warFarin dosing.
The Effect of CYP2C9 and VKORC1 Genetic Polymorphism on Warfarin Dose Requirements in a Sample of Iraqi Patients
TLDR
New warfarin-dosing algorithm was developed based on CYP2C9*3 and VKORC1genotypes for predicting the required dose of warFarin.
Evaluation of CYP2C9 and VKORC1 gene variants that may result in warfarin dosage sensitivity and poor pregnancy outcomes
TLDR
Predict the maintenance dose of warfarin in SA black patients better, thereby reducing the risk of adverse effects, and identify those at risk of having a poor pregnancy outcome.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Genetic modulation of oral anticoagulation with warfarin.
TLDR
The incidence of bleeding complications in CYP2C9*2 and CYP9*3 carriers was significantly higher than that in noncarriers and interacted with the presence of local bleeding sources.
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
TLDR
An association between CYP2C9 genotype and warfarin sensitivity is confirmed, however, the possession of a variant allele does not increase the likelihood of severe over-anticoagulation or stability of anticoagulations during long-term therapy.
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
TLDR
The results of this study suggest that the CYP2C9*2 and CYP1c9*3 polymorphisms are associated with an increased risk of overanticoagulation and of bleeding events among patients in a warfarin anticoagulated clinic setting, although small numbers in some cases would suggest the need for caution in interpretation.
Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Cytochrome P4502C9 (CYP2C9) is largely responsible for terminating the anticoagulant effect of racemic warfarin via hydroxylation of the pharmacologically more potent S-enantiomer to inactive
Cytochrome P450 polymorphisms are associated with reduced warfarin dose.
BACKGROUND Warfarin use is complicated by an erratic dose response. Interpatient variability associated with warfarin therapy may be partly attributable to polymorphisms of the cytochrome P450 (CYP)
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
TLDR
The gene vitamin K epoxide reductase complex subunit 1 (VKORC1), which encodes a small transmembrane protein of the endoplasmic reticulum, is identified, by using linkage information from three species, to be involved in two heritable human diseases.
Genetic analysis of the human cytochrome P450 CYP2C9 locus.
TLDR
Polymerase chain reaction-based assays are developed to distinguish all seven CYP2C9 cDNA sequences, and have determined their allele frequencies in the Caucasian population, allowing the prediction of CYP 2C9 phenotype, thus identifying those individuals who may exhibit different drug pharmacokinetics for CYP1C9 substrates.
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
TLDR
Clinical investigations evaluating the metabolic consequences in individuals expressing the CYP2C9*2, *3, *4, *5, or *6 alleles are required before large-scale clinical genotyping can be recommended.
Identification of the gene for vitamin K epoxide reductase
Vitamin K epoxide reductase (VKOR) is the target of warfarin, the most widely prescribed anticoagulant for thromboembolic disorders. Although estimated to prevent twenty strokes per induced bleeding
...
1
2
3
4
5
...